Don’t Assume MS Causes All Changes in Patients’ Disability
As the average age of people with multiple sclerosis (MS) increases, it becomes even more critical...
Read MoreApr 9, 2021
As the average age of people with multiple sclerosis (MS) increases, it becomes even more critical...
Read MoreApr 9, 2021
As the average age of people with multiple sclerosis (MS) increases, it becomes even more critical...
Read MoreApr 5, 2021
Prior research has shown that levels of serum neurofilament light (sNfL), a promising biomarker of...
Read MoreMar 18, 2021
Obesity is a health problem that can exacerbate the symptoms of multiple sclerosis (MS). In the...
Read MoreMar 15, 2021
As the average age of people with multiple sclerosis (MS) increases, it becomes even more critical...
Read MoreOct 16, 2020
Once-monthly injections allows patients to control their treatment schedule In a group of...
Read MoreOct 2, 2020
The interim analysis of the EXCHANGE trial suggest that, for patients with relapsing multiple sclerosis, immediate conversion from oral/injectable disease modifying therapies to siponimod without any washout period (within 24...
Read MoreOct 2, 2020
Neutrophil granulocyte (NG)-specific biomarkers have high sensitivity and specificity for rapid differentiation between acute neuromyelitis optica spectrum disorders (NMOSD), anti-MOG-antibody associated disease (MOGAD), and...
Read MoreOct 2, 2020
During pregnancy and the disease-modifying treatment (DMT)-free postpartum period, serum neurofilament-light (sNfL) levels were augmented [1]. This increase was independent of relapses, suggesting increased subclinical disease...
Read MoreOct 2, 2020
Neurite orientation dispersion and density imaging (NODDI) can detect brain microstructural and metabolic alterations after the first demyelinating event in MS [1]. There was increased axonal dispersion in normal-appearing white...
Read MoreOct 2, 2020
People with MS are not more susceptible to COVID-19 infection than the UK general population, suggest results of the largest community-based study of COVID-19 in people with MS worldwide [1]. During lockdown, with strict...
Read MoreOct 2, 2020
No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...
Read MoreOct 2, 2020
Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...
Read MoreOct 2, 2020
Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...
Read MoreOct 2, 2020
Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and understand sex differences. There seem to be unexplored sources of bias in observational and interventional studies. Greater attention is...
Read MoreOct 2, 2020
Masitinib is a first-in-class tyrosine kinase inhibitor targeting the innate immune system. Results from a randomised trial with innovative design features indicated it may present a new treatment option for primary progressive...
Read MoreOct 2, 2020
Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Read MoreOct 2, 2020
For one of the most prevalent a specific symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized...
Read MoreOct 2, 2020
In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....
Read MoreOct 2, 2020
Only a few weeks prior to MSVirtual2020, the fully human anti-CD20 monoclonal antibody ofatumumab...
Read More